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INTRODUCTION
Testosterone is a potent anabolic hormone that promotes appendicular lean mass and muscle strength in men over a wide age span (Bhasin et al., 1996 (Bhasin et al., , 2001 (Bhasin et al., , 2005 . The increase in lean mass and muscle strength is related to the administered testosterone dose and to the circulating on-treatment serum testosterone concentrations (Herbst & Bhasin, 2004) . Suppression of testosterone production during androgen deprivation therapy for prostate cancer results in loss of muscle mass, reduced muscle strength, and propensity toward falls, further supporting the anabolic and function-promoting properties of testosterone (Bylow et al., 2008; Storer et al., 2012) . Serum testosterone levels decrease in men with aging, and although this age-related decline is of a much less magnitude than that associated with androgen deprivation therapy, this decline has also been associated with reduced lean mass, low muscle strength, and predisposition to falls (van den Beld et al., 2000; Orwoll et al., 2006; Wu et al., 2010; Chin et al., 2012) .
The muscles of the trunk, which include the abdominal and paraspinal muscles, are commonly referred to as the 'core muscles' because of their importance in maintaining posture, balance, and stability to the vertebral column and therefore play an important role in the prevention of falls (Granacher et al., 2013) . Core muscle strength has also been associated with successful performance of activities of daily living in old age (Granacher et al., 2013) , while its loss leads to loss of balance and predisposition to falls (Granacher et al., 2008) . In addition to the core muscles of the trunk, the obturator internus muscle is also important for hip stabilization and motion of the lower extremity and its weakness with aging could contribute to mobility limitation and falls (Retchford et al., 2013; Hodges et al., 2014) . In spite of their importance, the responsiveness of these important groups of muscles to testosterone is not known.
Another important group of muscles that have relevance to aging is the muscles of the pelvic floor. The muscles of the pelvic floor subserve an important role in erectile function and in maintaining urinary and fecal continence (Dorey, 2005) . The levator ani muscle forms the bulk of the pelvic floor and is important in maintaining continence and support for pelvic organs, while the ischiocavernosus muscle contributes to penile rigidity (Clement & Giuliano, 2015) . Indeed, physical exercises directed toward strengthening pelvic floor muscles improve erectile function and intercourse satisfaction (Meldrum et al., 2014) . Similarly, it has been suggested that use of anabolic agents in conjunction with pelvic floor exercises might be useful in the treatment of pelvic floor disorders (Omar & Alexander, 2013) .
Although many clinical trials have assessed the efficacy of testosterone therapy on appendicular muscle mass, its efficacy in increasing the mass of the trunk and pelvic muscles has not been investigated systematically. The paucity of data on these muscle groups might be due to the fact that conventional imaging methods, such as the dual-energy X-ray absorptiometry (DXA) scan, are not able to assess the area of these muscles. Furthermore, the measurement of lean trunk mass with DXA scan is confounded by abdominal parenchymal organs. A previous study of men who had been treated for rectal cancer reported a positive association between endogenous serum testosterone levels and psoas major muscle area (Buchli et al., 2015) , while only one small trial showed that testosterone replacement in hypogonadal men increased the area of the paraspinal muscles assessed with computed tomography scan (Leifke et al., 1998) . However, the dose-dependent effects of testosterone replacement on the trunk core and pelvic muscle groups have not been studied. Magnetic resonance imaging (MRI) has emerged as the imaging modality of choice to analyze the trunk and pelvic muscle area (Cruz-Jentoft et al., 2010) . Therefore, we performed this proof-of-concept study using MRI to evaluate dose-response relationship of the trunk and pelvic muscles to testosterone administration in young healthy men who had previously participated in the 5a-Reductase (5aR) Trial (Bhasin et al., 2012) .
SUBJECTS AND METHODS

Study design and participants
As described previously (Bhasin et al., 2012) , the 5a-Reductase (5aR) Trial was a randomized, double-blind, placebo-controlled parallel-group trial. The trial was designed to evaluate the importance of the conversion of testosterone to 5a-dihydrotestosterone (DHT) on the effects of testosterone on muscle mass, strength, sexual function, prostate volume, sebum production, hematocrit, and blood lipids in healthy eugonadal men. The first participant was enrolled in May 2005, and the last participant completed the trial in June 2010. The study was approved by the institutional review board of Boston University and Brigham and Women's Hospital, and all participants gave written informed consent. The trial is registered at ClinicalTrials.gov (NCT00493987).
The details of eligibility and exclusion criteria for the 5aR trial have been published (Bhasin et al., 2012) . Briefly, healthy men aged 18-50 years with normal testosterone levels (300-1200 ng/ dL) were eligible to enroll in the study. Men who had a history of prostate cancer, uncontrolled hypertension, erythrocytosis, prostate-specific antigen (PSA) greater than 4 ng/mL, aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the upper limit of normal, creatinine greater than 2 mg/ dL, or were receiving glucocorticoids, growth hormone, androgens, or 5a-reductase inhibitors were excluded.
Interventions
Endogenous testosterone production was suppressed by monthly intramuscular injections of 7.5 mg of leuprolide acetate (Lupron depot; TAP Pharmaceuticals, Lake Forest, IL, USA) starting on the day of randomization. Concurrently, the subjects received weekly intramuscular injections of one of four graded doses (50, 125, 300, or 600 mg) of testosterone enanthate (TE) selected to generate plasma testosterone levels ranging from subphysiological to supraphysiological. These doses were based on dose-response studies in healthy men (Bhasin et al., 2001 (Bhasin et al., , 2005 . A randomization table was used to allocate individuals to one of eight study groups (placebo plus 50, 125, 300, or 600 mg/ week TE or 2.5 mg/day of dutasteride plus 50, 125, 300, or 600 mg/week of TE for 20 weeks).
Magnetic resonance imaging (MRI)
Participants underwent magnetic resonance imaging (MRI) using a 1.5T system (MRI; Philips Medical Systems, Andover, MA, USA) of the abdomen and pelvis, using an axial mixed fast spin-echo pulse sequence (slice thickness: 5 mm; interslice distance: 2 mm) at baseline and the 20th week of treatment. The mixed fast spin-echo pulse sequence was used to generate T1 and T2 maps (Farraher et al., 2005) . The thickness of the section was 5 mm, image matrix size 256 9 256 or 320 9 320; echo time (TE): 100/105. The changes in pelvic muscle area were analyzed at TE 6.452/11.052.
The image analysis of trunk muscles was performed using axial plane images at the third lumbar vertebrae (L 3 ) (Zhou et al., 2000; Shen et al., 2004; Mourtzakis et al., 2008; MacDonald et al., 2011; Baker et al., 2012) . The inter-reader and intrareader reproducibility of manual analysis of body composition using MRI scans have shown reliability of this approach (MaurovichHorvat et al., 2007; MacDonald et al., 2011) . A single experienced operator (JT), who was blinded to treatment assignment, performed all image analyses. Muscles were manually traced, and the traced area was calculated in an automated fashion using OsiriX version 7.5.1 (Pixmeo, Bernex, Geneva, Switzerland). Muscle area measured was reported in cm 2 and was standardized by dividing it by height in meters squared (Mourtzakis et al., 2008) . Earlier studies using this methodology have demonstrated high reproducibility (Buchli et al., 2015) . For the pelvic floor, we performed test-retest variability by performing measurements on 10 randomly selected participants. Pelvic floor area test-retest difference was on average 0.31 AE 1.06% (median 0.37%, range À2.07% to 2.3%) suggesting high reproducibility.
Outcomes
Psoas muscle
The primary outcome of this study was the change in the axial area of the psoas major muscle at the level of the L 3 vertebrae based on the method described by Taguchi et al. (Mourtzakis et al., 2008) . Both psoas major muscles were located and traced separately. An example of the traced outline of the muscle is presented in Fig. 1A .
Paraspinal muscles
The lumbar paraspinal muscles at L 3 (erector spinae and quadratus lumborum) were located using the same methodology as for psoas major. Each muscle was traced separately (Fig. 1A) .
Total abdominal muscle mass
Total area of the abdominal muscles at the L 3 level was computed by adding the areas of psoas major muscle, paraspinal muscles, and the anterior abdominal wall muscles (which included transverse abdominis, internal and external obliques, and rectus abdominis muscles (Fig. 1A) ).
Obturator internus muscle
The obturator internus muscle originates from the membrane of the foramen obturatum and inserts at the major trochanter of the femur. It stabilizes the hip joint and assists in outwards rotation of the thigh. The area of obturator internus muscle was measured using the axial slice that contained the largest combined trans-axial widths (Fig. 1D ).
The ischiocavernosus muscle
The ischiocavernosus muscle originates from ischial ramus and inserts in crus penis; this muscle is responsible for maintaining penile rigidity during erection. The area of ischiocavernosus muscle was measured using the axial slice that contained the largest combined trans-axial widths (Fig. 1B) .
Pelvic floor muscle area
Pelvic floor muscles, which include the levator ani muscle, were measured using an axial slice in the area distal to the prostate and proximal to the penile bulb. The rectum and the urethra were carefully excluded from measurement. The pelvic floor muscles are important for urinary and fecal continence and also support abdominal and pelvic organs (Fig. 1C) .
Hormone assays
Morning blood samples for measurement of sex steroids were collected at baseline and at the end of the trial. Both total testosterone and dihydrotestosterone (DHT) were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with a sensitivity of 2 ng/dL (Bhasin et al., 2011) . The interassay coefficient of variation for testosterone assay was 7.7% at 241 ng/dL, 4.4% at 532 ng/dL, and 3.3% at 1016 ng/dL of testosterone. Free testosterone levels were calculated (Mazer, 2009) . Sex hormone-binding globulin (SHBG) was measured using an immunofluorometric assay with sensitivity of 2.5 nmol/L (Basaria et al., 2010) .
Statistical analysis
Descriptive statistics for each testosterone dose were presented as means and standard deviations. Model assumptions and distribution of outcomes were investigated graphically. Associations of muscle measurements with testosterone dose and testosterone levels were explored using linear regression models. Main outcome-standardized change in muscle area from baseline-was defined as the change in muscle area divided by height-squared. Additionally, the absolute change from baseline was also considered for all linear regression models. Linear regressions for height-squared standardized outcomes were adjusted for baseline measurements and two clinically desirable factors: age and SHBG. Additionally, BMI adjustment was included in the regression analyses of non-standardized muscle measurements. Adjusted parameter estimates of outcomes with corresponding 95% CIs were provided per 100 mg/week dose change in testosterone enanthate. To further explore relative strength of dose effect on change in muscle measurements, partial R-squared metrics were calculated. Associations between total and free testosterone levels and muscle 66 Andrology, 2018, 6, 64-73 outcomes were assessed with R-squared and corresponding pvalues and graphically presented with scatter plots. All statistical tests were two-sided with alpha level 0.05. Analyses were performed using SAS v.9.3 (SAS Institute, Cary, NC, USA) and R software version 2.15.1.
RESULTS
Participants
A total of 3792 men were screened, and 189 met the eligibility criteria. One hundred and thirty-nine men were randomized, and 102 completed the trial. Out of the 102 subjects who completed the trial, 76 underwent MRI scans both at baseline and at the end of treatment and formed the analytic sample.
As reported previously, the dutasteride treatment did not yield different response for muscle mass or strength measures compared to the placebo during testosterone administration (Bhasin et al., 2012) . Similarly, initial assessments of the trunk and pelvic muscle areas in the dutasteride and placebo groups showed no differences; therefore, the two arms were combined to yield four groups based on testosterone regimens.
The baseline characteristics of the participants are described in Table 1 . Mean (SD) age was 37.3 (8.2) years, and mean body mass index (weight in kg divided by height in m 2 ) was 26.6 (3.9).
Hormone levels
Changes in serum hormone levels in men included in these analyses are summarized in Table 2 . Total testosterone and free testosterone concentrations showed a positive linear association with testosterone dose (p < 0.001, partial R 2 = 0.215 and p < 0.001, partial R 2 = 0.203, respectively) (Fig. 2) .
Changes in the trunk muscles
The change in the standardized psoas muscle area ranged from a reduction of 4.8% in the lowest testosterone dose regimen (50 mg/wk) to an increase of 9.7% in the highest dose group (600 mg/wk). Testosterone administration was associated with a dose-dependent increase in psoas cross-sectional area. The change in both the absolute and the standardized psoas major muscle areas showed a significant positive association with testosterone dose (p < 0.001, partial R 2 = 0.297 and p < 0.001, partial R 2 = 0.311, respectively; Table 3 and Fig. 3 ).
The absolute and standardized area of the paraspinal muscles (p < 0.001, partial R 2 = 0.450 and p < 0.001, partial R 2 = 0.468, respectively) and the abdominal wall muscles also displayed dose-response relationships (p < 0.001, partial R 2 = 0.340 and p < 0.001, partial R 2 = 0.373, respectively) ( Table 3 and Fig. 3 ).
Both the absolute and standardized total abdominal muscle area also showed positive linear associations with the testosterone dose (p < 0.001, partial R 2 = 0.481 and p < 0.001, partial R 2 = 0.494, respectively; Table 3 and Fig. 3 ). Similar to total testosterone, serum free testosterone concentrations also showed positive associations with total abdominal muscle area (Fig. 4) .
Changes in the pelvic muscles
The cross-sectional area of the obturator internus muscle showed dose-response relationship with testosterone; both the absolute area as well as the muscle area standardized for height showed an increase (p < 0.001, partial R 2 = 0.175 and p < 0.001, partial R 2 = 0.192, respectively; Table 3 and Fig. 3 ). Similar associations were seen with free testosterone (Fig. 4) . The ischiocavernosus muscle area, both absolute and standardized, showed significant linear associations with testosterone dose (p = 0.041, partial R 2 = 0.068 and p = 0.060, partial R 2 = 0.059, respectively) as well as with serum concentrations of both total and free testosterone (total testosterone p = 0.008, free testosterone p = 0.003; Figs 3 and 4) . The average increase in the cross-sectional area of the ischiocavernosus muscle was 22% among men receiving the dose of 600 mg/wk. Similarly, 68 Andrology, 2018, 6, 64-73 significant dose-response relationship was seen between the testosterone dose and the change in pelvic floor muscles, including levator ani (p < 0.001, partial R 2 = 0.402).
DISCUSSION
The present study shows that exogenous testosterone administration induced a dose-dependent increase in the muscles of the trunk and pelvis. Additionally, testosterone administration dose-dependently increased the hip-stabilizing obturator internus muscle and also the ischiocavernosus muscle that has an important role in erectile function. These results are consistent with a previous small study showing that testosterone replacement increased volume of the paraspinal muscles in hypogonadal men (Leifke et al., 1998) . We also show that increments in the area of these trunk and pelvic muscles were correlated with on-treatment total and free serum testosterone levels. These findings suggest that these muscle groups in men are as responsive to testosterone administration as the appendicular muscles and can be potential targets of intervention in frail older men who are at risk for falls and men who have pelvic floor disorders (Granacher et al., 2008 (Granacher et al., , 2013 . Muscle area change is expressed in square centimeters. Standardized (Std) muscle change was defined as muscle change divided by height-squared (cm 2 /m 2 ). *Values presented for parameter estimates and 95% CIs of muscle area change are per 100 unit increase (increase of 100 mg of testosterone enanthate per week) in the dose regimen. **Overall R-squared values for linear regression model with adjustments. The core muscles of the trunk are considered 'dynamic stabilizers', and they play a vital role in providing stability and functional movement to the vertebral column; atrophy of these muscles can lead to spinal instability and predisposition to falls (Danneels et al., 2000; Kim et al., 2014) . Similar to appendicular muscles, the core muscles also undergo atrophy in wasting conditions. For example, among patients with hypercortisolemia and liver cirrhosis, significant atrophy of the psoas major muscle Figure 4 Scatter plots of standardized muscle area change on total and free testosterone level change. R 2 and p-values represent association between standardized body composition and total and free testosterone level change calculated from simple linear regression model. [Colour figure can be viewed at wileyonlinelibrary.com].
70 Andrology, 2018, 6, 64-73 is seen on MRI (Miller et al., 2011; Durand et al., 2014) . Similarly, prolonged bed rest results in atrophy of these muscles (Hides et al., 2007) . Chronic low back pain, which is common in older patients, is also associated with atrophy of the trunk muscles and predisposes these patients to mobility limitation and loss of balance (Wan et al., 2015) . Thus, it appears that truncal muscles are responsive to both anabolic and catabolic influences similar to the appendicular muscles and these changes are detectable with much more clarity with MRI.
Obturator internus muscle is important in stabilization and external rotation of the hip (Yoo et al., 2015; Byrne et al., 2017) . Its responsiveness to testosterone suggests potential beneficial impact in the elderly by stabilizing the hip during walking.
Older men are at increased risk for organ prolapse, incontinence, and sexual dysfunction. The prevalence of urinary and fecal incontinence increases with aging (Shamliyan et al., 2009; Ng et al., 2015; Berghmans et al., 2016; Bernard et al., 2016) , and weakness of the pelvic floor muscles contributes to the increased risk of incontinence (Ng et al., 2015; Berghmans et al., 2016; Bernard et al., 2016) . Age-related decline in serum testosterone levels may further contribute to the weakening of the muscles of the pelvic floor. This is of particular concern in men with colorectal cancer who undergo pelvic radiation, which may negatively affect the pelvic floor and may lower testosterone levels due to its toxic effect on the testes (Buchli et al., 2011 (Buchli et al., , 2015 . In this study, the ischiocavernosus muscle, which has an important role in elevating the anus and in maintaining the rigidity of the erect penis (Clement & Giuliano, 2015) , showed the most increase in cross-sectional area (up to 22% increase in the highest dose group). Our observation that the pelvic floor muscles are responsive to testosterone therapy suggests that future trials of testosterone therapy should be conducted in androgendeficient men with prior history of pelvic surgery or radiation who are experiencing incontinence and organ prolapse (Buchli et al., 2015) .
The present study has several strengths and some limitations. The strengths include the randomized double-blind study design and the inclusion of young healthy men (which obviated confounding due to age or comorbid conditions). We used a range of testosterone doses that resulted in a range of circulating testosterone concentrations, extending from subphysiological to supraphysiological levels. We used state-of-the-art MRI method to evaluate these muscles and all images were analyzed by one expert investigator (J.T.), hence, reducing inter-observer variability. Furthermore, manual tracing of image sets comprised of several axial slices was performed, thus allowing exact tracking of muscles based on the traced boundaries (Baker et al., 2012; Taguchi et al., 2016) . Lastly, the manual tracing method used in this study compensates for any potential image artifacts. The limitation of this study is that evaluation of trunk and pelvic muscles was not pre-specified hypotheses of the trial; therefore, they should be viewed as exploratory. The sample size was also relatively small; however, this is the largest study conducted to date that assessed these muscle groups and we were able to detect dose-responsiveness with this sample. Although this study enrolled younger men, previous studies have shown that older men are as responsive to testosterone administration as younger men (Bhasin et al., 2005) . Therefore, this study lays the groundwork for a future trial to evaluate efficacy of testosterone administration on these muscle groups in older men.
CONCLUSION
We found that muscles of the trunk and pelvis are androgen responsive and manifest dose-response relationship. Based on these findings, these muscle groups could be potential targets for intervention with testosterone in frail older men who are at risk for falls and in men with pelvic floor disorders. 
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